Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels


GT Biopharma CEO, Tony Cataldo to Present at Sir Anthony Ritossa's Global


PR Newswire | Jun 24, 2021 08:01AM EDT

Family Office Investment Summit

06/24 07:00 CDT

GT Biopharma CEO, Tony Cataldo to Present at Sir Anthony Ritossa's Global Family Office Investment Summit BEVERLY HILLS, Calif, June 24, 2021

BEVERLY HILLS, Calif, June 24, 2021 /PRNewswire/ -- GT Biopharma, Inc. ("GT Biopharma" or the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager (TriKE(tm)) protein biologic technology platform, today announced that GT Biopharma CEO, Tony Cataldo will be presenting as a VIP speaker at the upcoming Sir Anthony Ritossa's Global Family Office Investment Summit in Monaco from June 30 to July 2, 2021.

The Sir Anthony Ritossa's Global Family Office Investment Summit in Monaco is one of a series of international summits held annually as a platform for exceptional networking between Family Offices and Thought Leaders from all over the world. Summit delegations consist of prestigious family offices, private investors, sheikhs, royal families and leading businesses from 30+ countries representing more than $4.5 trillion in wealth.

About GT Biopharma, Inc.GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE(tm) NK cell engager platform. Our TriKE(tm) platform is designed to harness and enhance the cancer killing abilities of a patient's immune system's natural killer cells (NK cells). GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE(tm) technology. For more information, please visit gtbiopharma.com.

Investor Contact: Investor and Media Relations Contact:

Brendan Payne David Castaneda

Client Lead David@gtbiopharma.com

Stern Investor Relations, Inc. 414-351-9758

brendan.payne@sternir.com

212-362-1200

View original content to download multimedia: http://www.prnewswire.com/news-releases/gt-biopharma-ceo-tony-cataldo-to-present-at-sir-anthony-ritossas-global-family-office-investment-summit-301318854.html

SOURCE GT Biopharma, Inc.






Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC